Cap

Zacks Small Cap Research – TELO Announces Breakthrough – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro

by
Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketing shift from BioLine’s internal team to Ayrmid’s subsidiary Gamida Cell. Gamida cell is commercializing Omisirge, a cell therapy for treating blood cancers in patients who need a stem cell transplant. … Read more

Zacks Small Cap Research – SDOT: Sadot Group Announces Appointment of new CEO – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT New CEO On February 13, 2025, Sadot Group (NASDAQ:SDOT) announced the appointment of Catia Jorge as new Chief Executive Officer. Ms. Jorge has nearly 30 years of experience in agricultural markets, commodity trading, and operational leadership. Most recently, she served as Brazil Country Head … Read more

Zacks Small Cap Research – MDAI: Pivotal Data Analysis Complete – Go Health Pro

by
Zacks Small Cap Research – MDAI: Pivotal Data Analysis Complete – Go Health Pro

By John Vandermosten, CFA NASDAQ:MDAI READ THE FULL MDAI RESEARCH REPORT Since reporting third quarter results in November, Spectral AI, Inc. (NASDAQ:MDAI) has continued to advance its burn program in burn center populations, pediatric burn in emergency departments and with the SnapShot M portable device. Most importantly, Spectral has finished enrollment and evaluation of all … Read more

Zacks Small Cap Research – ARWR: Multiple Catalysts Ahead in 2025… – Go Health Pro

by

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for plozasiran for the treatment of familial chylomycronemia syndrome (FCS), with a Prescription Drug User Fee Act … Read more

x